CellGenix® rh IL-3 (GMP Grade)
Top Features for Recombinant Human Interleukin-3:
- Optimal use for expansion of HSCs
- ADCF Level 2
- High purity to ensure the safety of your process
- Available in two different grades (Preclinical and GMP grade)
- Intended for preclinical ex vivo use
- GMP transferable: Seamless transition from preclinical development to commercial manufacturing
- Intended for clinical ex vivo use
- Endotoxin Level ≤ 50 EU/mg
- Manufactured in accordance with applicable GMP guidelines
- FDA Drug Master File (DMF) available
- Technical and regulatory support available
- Price (USD):
- Catalog No.:
*Custom/bulk order quotes are provided within 72 hours of request.
Letter of Authorization (LOA)
Place a request for a Letter of Authorization (LOA) for our Drug Master File (FDA)
CellGenix® rh Cytokines - Preclinical vs GMP
Both product grades are produced under the same conditions in a GMP facility, ensuring an equal product quality and performance. We offer a more comprehensive QC testing including tighter specifications and documentation for our GMP products: CellGenix® rh Cytokines - Preclinical vs GMP
CellGenix® Recombinant Human Interleukin-3 (IL-3) is an animal-derived component-free product. It is produced in a dedicated animal-free GMP facility. IL-3 is used in the cell and gene therapy space for the ex vivo expansion of hematopoietic stem cells (HSCs).
CellGenix® Recombinant Human IL-3 is produced following all applicable GMP guidelines and allows for the safe use in accordance with USP Chapter <1043>, Ph. Eur. General Chapter 5.2.12 and ISO 20399:2022.
CellGenix® GMP cytokines are provided with documented evidence of purity, potency, consistency and stability. In combination with our expert regulatory and technical support this will help simplify your raw material qualification and validation efforts. Please refer to Certificate of Analysis for the exact expiry date and batch specific activity.
Expiry: ≥ 6 months from date of shipping
Please refer to Certificate of Analysis https://my.sartorius.com/login for the exact expiry date and the batch specific activity.
We have submitted Drug Master Files (DMFs) to US Health Authorities to support our customers’ regulatory activities. These Master Files can be cross-referenced through Letters of Authorization (LOAs) in Marketing Authorizations, IND, BLA, NDA, ANDA or other DMF applications. Submit your Authorization Request here https://cellgenix.com/dmf-letter-of-authorization-request-form-2/
ApplicationClinical ex vivo use (small)
Cell & Gene Therapy
- Cell & Gene Therapy
Activity0.9 – 3.6 x 106 IU/mg
GMP ComplianceThis product was manufactured in accordance with applicable Good Manufacturing Practice (GMP) guidelines.
Endotoxin≤ 50 EU/mg
FormulationLyophilized from a 200 µl of a 0.2 µm-filtered solution containing 10 mM sodium phosphate and 50 mM sodium chloride, pH 7.2
Molecular Weight (kDa)15.2 kDa